Cargando…
A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 re...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675480/ https://www.ncbi.nlm.nih.gov/pubmed/36136607 http://dx.doi.org/10.1172/jci.insight.162695 |
_version_ | 1784833383222738944 |
---|---|
author | Schmitt, Erica G. Toth, Kelsey A. Risma, Samuel I. Kolicheski, Ana Saucier, Nermina Berríos, Rafael J. Feliciano Greenberg, Zev J. Leiding, Jennifer W. Bleesing, Jack J. Thatayatikom, Akaluck Schuettpelz, Laura G. Edwards, John R. Vogel, Tiphanie P. Cooper, Megan A. |
author_facet | Schmitt, Erica G. Toth, Kelsey A. Risma, Samuel I. Kolicheski, Ana Saucier, Nermina Berríos, Rafael J. Feliciano Greenberg, Zev J. Leiding, Jennifer W. Bleesing, Jack J. Thatayatikom, Akaluck Schuettpelz, Laura G. Edwards, John R. Vogel, Tiphanie P. Cooper, Megan A. |
author_sort | Schmitt, Erica G. |
collection | PubMed |
description | Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result in a PIRD with a broad clinical spectrum. Studies in patients have documented a decreased frequency of FOXP3(+) Tregs and an increased frequency of Th17 cells in some patients with active disease. However, the mechanisms of disease pathogenesis in STAT3 GOF syndrome remain largely unknown, and treatment is challenging. We developed a knock-in mouse model harboring a de novo pathogenic human STAT3 variant (p.G421R) and found these mice developed T cell dysregulation, lymphoproliferation, and CD4(+) Th1 cell skewing. Surprisingly, Treg numbers, phenotype, and function remained largely intact; however, mice had a selective deficiency in the generation of iTregs. In parallel, we performed single-cell RNA-Seq on T cells from STAT3 GOF patients. We demonstrate only minor changes in the Treg transcriptional signature and an expanded, effector CD8(+) T cell population. Together, these findings suggest that Tregs are not the primary driver of disease and highlight the importance of preclinical models in the study of disease mechanisms in rare PIRD. |
format | Online Article Text |
id | pubmed-9675480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-96754802022-11-21 A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice Schmitt, Erica G. Toth, Kelsey A. Risma, Samuel I. Kolicheski, Ana Saucier, Nermina Berríos, Rafael J. Feliciano Greenberg, Zev J. Leiding, Jennifer W. Bleesing, Jack J. Thatayatikom, Akaluck Schuettpelz, Laura G. Edwards, John R. Vogel, Tiphanie P. Cooper, Megan A. JCI Insight Research Article Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result in a PIRD with a broad clinical spectrum. Studies in patients have documented a decreased frequency of FOXP3(+) Tregs and an increased frequency of Th17 cells in some patients with active disease. However, the mechanisms of disease pathogenesis in STAT3 GOF syndrome remain largely unknown, and treatment is challenging. We developed a knock-in mouse model harboring a de novo pathogenic human STAT3 variant (p.G421R) and found these mice developed T cell dysregulation, lymphoproliferation, and CD4(+) Th1 cell skewing. Surprisingly, Treg numbers, phenotype, and function remained largely intact; however, mice had a selective deficiency in the generation of iTregs. In parallel, we performed single-cell RNA-Seq on T cells from STAT3 GOF patients. We demonstrate only minor changes in the Treg transcriptional signature and an expanded, effector CD8(+) T cell population. Together, these findings suggest that Tregs are not the primary driver of disease and highlight the importance of preclinical models in the study of disease mechanisms in rare PIRD. American Society for Clinical Investigation 2022-11-08 /pmc/articles/PMC9675480/ /pubmed/36136607 http://dx.doi.org/10.1172/jci.insight.162695 Text en © 2022 Schmitt et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Schmitt, Erica G. Toth, Kelsey A. Risma, Samuel I. Kolicheski, Ana Saucier, Nermina Berríos, Rafael J. Feliciano Greenberg, Zev J. Leiding, Jennifer W. Bleesing, Jack J. Thatayatikom, Akaluck Schuettpelz, Laura G. Edwards, John R. Vogel, Tiphanie P. Cooper, Megan A. A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice |
title | A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice |
title_full | A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice |
title_fullStr | A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice |
title_full_unstemmed | A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice |
title_short | A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice |
title_sort | human stat3 gain-of-function variant confers t cell dysregulation without predominant treg dysfunction in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675480/ https://www.ncbi.nlm.nih.gov/pubmed/36136607 http://dx.doi.org/10.1172/jci.insight.162695 |
work_keys_str_mv | AT schmittericag ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT tothkelseya ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT rismasamueli ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT kolicheskiana ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT sauciernermina ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT berriosrafaeljfeliciano ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT greenbergzevj ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT leidingjenniferw ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT bleesingjackj ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT thatayatikomakaluck ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT schuettpelzlaurag ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT edwardsjohnr ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT vogeltiphaniep ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT coopermegana ahumanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT schmittericag humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT tothkelseya humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT rismasamueli humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT kolicheskiana humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT sauciernermina humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT berriosrafaeljfeliciano humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT greenbergzevj humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT leidingjenniferw humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT bleesingjackj humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT thatayatikomakaluck humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT schuettpelzlaurag humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT edwardsjohnr humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT vogeltiphaniep humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice AT coopermegana humanstat3gainoffunctionvariantconferstcelldysregulationwithoutpredominanttregdysfunctioninmice |